Inclusion and ethics
RAS-mutated
The protocol was approved by the Ethics Committee CPP TOURS – Région Centre – Ouest 1 on 27 March 2017 under the number 2017T1-03 and was registered with the French national health products agency (ANSM). The French ethical authorities asked us to include only RAS-mutated metastatic CRC because RAS WT patients must receive an anti-EGFR in first-line of treatment, and it would be unethical to give a protocol without anti-EGFR for these patients. The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization for Good Clinical Practice guidelines and the CONSORT 2010 guidelines. All patients provided written informed consent to study procedures before enrollment. The study protocol was previously published elsewhere